Molecular insights and therapeutic implications of nanoengineered dietary polyphenols for targeting lung cancer: part II

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Allemani C, Weir HK, Carreira H et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972), 977–1010 (2015). • Highlights the lung cancer pathogenesis and global significance.
  MedlineGoogle Scholar
• 2. Chae DK, Ban E, Yoo YS, Kim EE, Baik JH, Song EJ. MIR-27a regulates the TGF-β signaling pathway by targeting SMAD2 and SMAD4 in lung cancer. Mol. Carcinog. 56(8), 1992–1998 (2017).
  Medline CASGoogle Scholar
• 3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
  MedlineGoogle Scholar
• 4. Herbst RS, Heymach JV, Lippman SM. Molecular origins of cancer: lung cancer. N. Engl. J. Med. 359(13), 1367–1380 (2008).
  Medline CASGoogle Scholar
• 5. Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for Cancer Research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J. Nutr. 150(4), 663–671 (2020).
  MedlineGoogle Scholar
• 6. Das SS, Verma PRP, Kar S, Singh SK. Quercetin-loaded nanomedicine as oncotherapy. In: Nanomedicine for Bioactives Rahman MBeg SKumar VAhmad F (Eds). Springer, Singapore (2020).
  Google Scholar
• 7. Cook NC, Samman S. Flavonoids – chemistry, metabolism, cardioprotective effects, and dietary sources. J. Nutr. Biochem. 7(2), 66–76 (1996).
  Google Scholar
• 8. Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic. Res. 22(4), 375–383 (1995).
  Medline CASGoogle Scholar
• 9. Budisan L, Gulei D, Zanoaga OM et al. Dietary intervention by phytochemicals and their role in modulating coding and non-coding genes in cancer. Int. J. Mol. Sci. 18(6), 1178 (2017).
  MedlineGoogle Scholar
• 10. Batra P, Sharma AK. Potential of flavonoids: recent trends and future perspectives. 3 Biotech 3(6), 439–459 (2013).
  MedlineGoogle Scholar
• 11. Zanoaga O, Braicu C, Jurj A, Rusu A, Buiga R, Berindan-Neagoe I. Progress in research on the role of flavonoids in lung cancer. Int. J. Mol. Sci. 20(17), 4291 (2019). •• Overview on the classification, mechanism and therapeutic effects of various flavonoids in lung cancer therapy.
  Medline CASGoogle Scholar
• 12. Xu Q, Zeng Y, Tang W et al. Multi-task joint learning model for segmenting and classifying tongue images using a deep neural network. IEEE J. Biomed. Health. Inf. 24(9), 2481–2489 (2020).
  MedlineGoogle Scholar
• 13. Li S, Yu Y, Bian X et al. Prediction of oral hepatotoxic dose of natural products derived from traditional Chinese medicines based on SVM classifier and PBPK modeling. Arch. Toxicol. 95(5), 1683–1701 (2021).
  Medline CASGoogle Scholar
• 14. Ferrazzano GF, Amato I, Ingenito A, Zarrelli A, Pinto G, Pollio A. Plant polyphenols and their anti-cariogenic properties: a review. Molecules 16(2), 1486–1507 (2011).
  Medline CASGoogle Scholar
• 15. Barkat HA, Das SS, Barkat MA, Beg S, Hadi HA. Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncol. 16(35), 2959–2979 (2020).
  CASGoogle Scholar
• 16. Cincin ZB, Unlu M, Kiran B, Bireller ES, Baran Y, Cakmakoglu B. Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small-cell lung cancer cells. Cell. Oncol. (Dordr.) 38(3), 195–204 (2015).
  MedlineGoogle Scholar
• 17. Xia R, Sheng X, Xu X, Yu C, Lu H. Hesperidin induces apoptosis and G0/G1 arrest in human non-small-cell lung cancer A549 cells. Int. J. Mol. Med. 41(1), 464–472 (2018).
  Medline CASGoogle Scholar
• 18. Jin CY, Park C, Hwang HJ et al. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol. Nutr. Food Res. 55(2), 300–309 (2011).
  Medline CASGoogle Scholar
• 19. Adigun TO, Joel IY, Bankole OO et al. Discovery of eriodictyol as putative exportin-1 inhibitor for non-small-cell lung cancer therapy. Preprints (2020). doi:10.20944/preprints202010.0477.v1.
  Google Scholar
• 20. Wang R, Zhu X, Wang Q et al. The anti-tumor effect of taxifolin on lung cancer via suppressing stemness and epithelial-mesenchymal transition in vitro and oncogenesis in nude mice. Ann. Transl. Med. 8(9), 590 (2020).
  Medline CASGoogle Scholar
• 21. Wang Q, Zhang L, Huang M, Zheng Y, Zheng K. Immunomodulatory effect of eriocitrin in experimental animals with benzo(a)pyrene-induced lung carcinogenesis. J. Environ. Pathol. Toxicol. Oncol. 39(2), 137–147 (2020).
  MedlineGoogle Scholar
• 22. Hung JY, Hsu YL, Ko YC et al. Didymin, a dietary flavonoid glycoside from citrus fruits, induces Fas-mediated apoptotic pathway in human non-small-cell lung cancer cells in vitro and in vivo. Lung Cancer 68(3), 366–374 (2010).
  MedlineGoogle Scholar
• 23. Santos EL, Maia BHLS, Teixeira APFD. Flavonoids: Classification, Biosynthesis and Chemical Ecology. In: Justino GC (Ed.). Flavonoids – From Biosynthesis to Human Health. IntechOpen, London (2017). doi:10.5772/67861Chapter 1.
  Google Scholar
• 24. Arunakaran J, Arunkumar R, Elumalai P, Senthilkumar S. Impact of quercetin, diallyl disulfide and nimbolide on the regulation of nuclear factor kappa B expression in prostate and breast cancer cell lines. Biochem. Pharmacol 2(4), 50 (2013).
  Google Scholar
• 25. Klimaszewska-Wisniewska A, Halas-Wisniewska M, Izdebska M, Gagat M, Grzanka A, Grzanka D. Antiproliferative and antimetastatic action of quercetin on A549 non-small-cell lung cancer cells through its effect on the cytoskeleton. Acta Histochem. 119(2), 99–112 (2017).
  Medline CASGoogle Scholar
• 26. Mukherjee A, Khuda-Bukhsh AR. Quercetin down-regulates IL-6/STAT-3 signals to induce mitochondrial-mediated apoptosis in a non-small-cell lung-cancer cell line, A549. J. Pharmacopuncture 18(1), 19–26 (2015).
  MedlineGoogle Scholar
• 27. Leung HWC, Lin CJ, Hour MJ, Yang WH, Wang MY, Lee HZ. Kaempferol induces apoptosis in human lung non-small carcinoma cells accompanied by an induction of antioxidant enzymes. Food Chem. Toxicol. 45(10), 2005–2013 (2007).
  Medline CASGoogle Scholar
• 28. Han X, Liu CF, Gao N, Zhao J, Xu J. Kaempferol suppresses proliferation but increases apoptosis and autophagy by up-regulating microRNA-340 in human lung cancer cells. Biomed. Pharmacother. 108, 809–816 (2018).
  Medline CASGoogle Scholar
• 29. Rajendran P, Maheshwari U, Muthukrishnan A et al. Myricetin: versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS-reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction. Mol. Cell. Biochem. 476(1), 57–68 (2021).
  Medline CASGoogle Scholar
• 30. Du Y, Jia C, Liu Y, Li Y, Wang J, Sun K. Isorhamnetin enhances the radiosensitivity of A549 cells through interleukin-13 and the NF-kappaB signaling pathway. Front. Pharmacol. 11, 610772 (2020).
  Medline CASGoogle Scholar
• 31. Zhang BY, Wang YM, Gong H et al. Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small-cell lung carcinoma (NSCLC). Int. J. Clin. Exp. Pathol. 8(1), 25–37 (2015).
  MedlineGoogle Scholar
• 32. Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. Sci. World J. 2013, 162750 (2013).
  Google Scholar
• 33. Bakhtiyari S, Zaherara M, Haghani K, Khatami M, Rashidinejad A. The phosphorylation of IRS1S307 and AktS473 molecules in insulin-resistant C2C12 cells induced with palmitate is influenced by epigallocatechin gallate from green tea. Lipids 54(2-3), 141–148 (2019).
  Medline CASGoogle Scholar
• 34. Sun H, Yin M, Hao D, Shen Y. Anti-cancer activity of catechin against A549 lung carcinoma cells by induction of cyclin kinase inhibitor p21 and suppression of cyclin E1 and P-AKT. Appl. Sci. 10(6), 2065 (2020).
  Google Scholar
• 35. Milligan SA, Burke P, Coleman DT et al. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small-cell lung cancer cells. Clin. Cancer Res. 15(15), 4885–4894 (2009).
  Medline CASGoogle Scholar
• 36. Fasco MJ, Hurteau GJ, Spivack SD. Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Mol. Cell. Endocrinol. 188(1-2), 125–140 (2002).
  Medline CASGoogle Scholar
• 37. Dubey S, Siegfried JM, Traynor AM. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol. 7(5), 416–424 (2006).
  Medline CASGoogle Scholar
• 38. Lian F, Bhuiyan M, Li YW, Wall N, Kraut M, Sarkar FH. Genistein-induced G2-M arrest, p21WAF1 upregulation, and apoptosis in a non-small-cell lung cancer cell line. Nutr. Cancer 31(3), 184–191 (1998).
  Medline CASGoogle Scholar
• 39. Lian F, Li Y, Bhuiyan M, Sarkar FH. p53-independent apoptosis induced by genistein in lung cancer cells. Nutr. Cancer 33(2), 125–131 (1999).
  Medline CASGoogle Scholar
• 40. Liu D, Yan L, Wang L, Tai W, Wang W, Yang C. Genistein enhances the effect of cisplatin on the inhibition of non-small-cell lung cancer A549 cell growth in vitro and in vivo. Oncol. Lett. 8(6), 2806–2810 (2014).
  MedlineGoogle Scholar
• 41. Tian T, Li J, Li B et al. Genistein exhibits effects via down-regulating FoxM1 in H446 small-cell lung cancer cells. Tumour Biol. 35(5), 4137–4145 (2014).
  Medline CASGoogle Scholar
• 42. Versantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small-cell lung cancer cells. Biochem. Pharmacol. 48(6), 1129–1136 (1994).
  Medline CASGoogle Scholar
• 43. Yang Y, Zang A, Jia Y et al. Genistein inhibits A549 human lung cancer cell proliferation via miR-27a and MET signaling. Oncol. Lett. 12(3), 2189–2193 (2016).
  Medline CASGoogle Scholar
• 44. Yu Y, Xing Y, Zhang Q et al. Soy isoflavone genistein inhibits hsa_circ_0031250/miR-873-5p/FOXM1 axis to suppress non-small-cell lung cancer progression. IUBMB Life 73(1), 92–107 (2021).
  Medline CASGoogle Scholar
• 45. Zhang Z, Jin F, Lian X et al. Genistein promotes ionizing radiation-induced cell death by reducing cytoplasmic Bcl-xL levels in non-small-cell lung cancer. Sci. Rep. 8(1), 328 (2018).
  Medline CASGoogle Scholar
• 46. Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF, De Luo B. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Mol. Biol. Rep. 39(4), 4971–4979 (2012).
  Medline CASGoogle Scholar
• 47. Guo S, Wang Y, Li Y, Li Y, Feng C, Li Z. Daidzein-rich isoflavones aglycone inhibits lung cancer growth through inhibition of NF-kappaB signaling pathway. Immunol. Lett. 222, 67–72 (2020).
  Medline CASGoogle Scholar
• 48. Chen J, Xu B, Sun J, Jiang X, Bai W. Anthocyanin supplement as a dietary strategy in cancer prevention and management: a comprehensive review. Crit. Rev. Food Sci. Nutr. 62(26), 7242–7254 (2021).
  MedlineGoogle Scholar
• 49. Pal HC, Sharma S, Strickland LR et al. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLOS ONE 8(10), e77270 (2013).
  Medline CASGoogle Scholar
• 50. Chen PN, Chu SC, Chiou HL, Kuo WH, Chiang CL, Hsieh YS. Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Cancer Lett. 235(2), 248–259 (2006).
  Medline CASGoogle Scholar
• 51. Singh P, Anand A, Kumar V. Recent developments in biological activities of chalcones: a mini review. Eur. J. Med. Chem. 85, 758–777 (2014).
  Medline CASGoogle Scholar
• 52. Wang Y, Hedblom A, Koerner SK et al. Novel synthetic chalcones induce apoptosis in the A549 non-small-cell lung cancer cells harboring a KRAS mutation. Bioorg. Med. Chem. Lett. 26(23), 5703–5706 (2016).
  Medline CASGoogle Scholar
• 53. Chen G, Zhou D, Li XZ et al. A natural chalcone induces apoptosis in lung cancer cells: 3D-QSAR, docking and an in vivo/vitro assay. Sci. Rep. 7(1), 10729 (2017). •• Outlines the therapeutic approaches for various dietary flavonoid-loaded nanoengineered systems in lung cancer therapy.
  MedlineGoogle Scholar
• 54. Dobrzynska M, Napierala M, Florek E. Flavonoid nanoparticles: a promising approach for cancer therapy. Biomolecules 10(9), 1268 (2020).
  Medline CASGoogle Scholar
• 55. Pelaz B, Alexiou C, Alvarez-Puebla RA et al. Diverse applications of nanomedicine. ACS Nano 11(3), 2313–2381 (2017).
  Medline CASGoogle Scholar
• 56. Wang S, Sun Z, Hou Y. Engineering nanoparticles toward the modulation of emerging cancer immunotherapy. Adv. Healthc. Mater. 10(5), 2000845 (2021).
  CASGoogle Scholar
• 57. Li S, Xu S, Liang X et al. Nanotechnology: breaking the current treatment limits of lung cancer. Adv. Healthc. Mater. 10(12), 2100078 (2021).
  CASGoogle Scholar
• 58. Vasilev K, Chen H, Murray P, Mantovani D. The potential of nanomaterials for drug delivery, cell tracking, and regenerative medicine 2014. J. Nanomater. 2015, 1–2 (2015).
  Google Scholar
• 59. Wang J, Zhou T, Liu Y, Chen S, Yu Z. Application of nanoparticles in the treatment of lung cancer with emphasis on receptors. Front. Pharmacol. 12, 781425 (2021).
  Medline CASGoogle Scholar
• 60. Zhou Q, Pan H, Li J. Molecular insights into potential contributions of natural polyphenols to lung cancer treatment. Cancers (Basel) 11(10), 1565 (2019).
  Medline CASGoogle Scholar
• 61. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189–207 (2001).
  Medline CASGoogle Scholar
• 62. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, Von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26(29), 5898–5906 (2005).
  Medline CASGoogle Scholar
• 63. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel. 65(1-2), 271–284 (2000).
  Medline CASGoogle Scholar
• 64. Yan J, Yao Y, Yan S, Gao R, Lu W, He W. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction. Nano Lett. 20(8), 5844–5852 (2020).
  Medline CASGoogle Scholar
• 65. Yang W, Liu W, Li X, Yan J, He W. Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2. J. Adv. Res. S2090-1232(22), 00121–7 (2022). • Focus on flavanol-loaded nanotherapeutics in lung cancer therapy.
  Google Scholar
• 66. Doroudian M, Macloughlin R, Poynton F, Prina-Mello A, Donnelly SC. Nanotechnology based therapeutics for lung disease. Thorax 74(10), 965 (2019).
  MedlineGoogle Scholar
• 67. Abbad S, Wang C, Waddad AY, Lv H, Zhou J. Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate. Int. J. Nanomed. 10, 305–320 (2015).
  MedlineGoogle Scholar
• 68. Jangid AK, Agraval H, Gupta N et al. Designing of fatty acid-surfactant conjugate based nanomicelles of morin hydrate for simultaneously enhancing anticancer activity and oral bioavailability. Colloids Surf. B Biointerfaces 175, 202–211 (2019).
  Medline CASGoogle Scholar
• 69. Jangid AK, Agraval H, Gupta N et al. Amorphous nano morin outperforms native molecule in anticancer activity and oral bioavailability. Drug Dev. Ind. Pharm. 46(7), 1123–1132 (2020).
  Medline CASGoogle Scholar
• 70. Velavan B, Divya T, Sureshkumar A, Sudhandiran G. Nano-chemotherapeutic efficacy of (-) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: involvement of reactive oxygen species mediated Nrf2/Keap1signaling. Biochem. Biophys. Res. Commun. 503(3), 1723–1731 (2018).
  Medline CASGoogle Scholar
• 71. Ahmad N, Ahmad R, Alrasheed RA et al. A chitosan–PLGA based catechin hydrate nanoparticles used in targeting of lungs and cancer treatment. Saudi J. Biol. Sci. 27(9), 2344–2357 (2020).
  Medline CASGoogle Scholar
• 72. Zhang L, Chen W, Tu G et al. Enhanced chemotherapeutic efficacy of PLGA-encapsulated epigallocatechin gallate (EGCG) against human lung cancer. Int. J. Nanomed. 15, 4417–4429 (2020).
  Medline CASGoogle Scholar
• 73. Chen BH, Hsieh CH, Tsai SY, Wang CY, Wang CC. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci. Rep. 10(1), 5163 (2020).
  Medline CASGoogle Scholar
• 74. Chen Y-J, Wang Z-W, Lu T-L et al. The synergistic anticancer effect of dual drug- (cisplatin/epigallocatechin gallate) loaded gelatin nanoparticles for lung cancer treatment. J. Nanomater. 2020, 9181549 (2020).
  Google Scholar
• 75. Yuan ZP, Chen LJ, Fan LY et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res. 12(10), 3193–3199 (2006).
  Medline CASGoogle Scholar
• 76. Tan BJ, Liu Y, Chang KL, Lim BK, Chiu GN. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int. J. Nanomed. 7, 651–661 (2012).
  Medline CASGoogle Scholar
• 77. Khonkarn R, Mankhetkorn S, Hennink WE, Okonogi S. PEG-OCL micelles for quercetin solubilization and inhibition of cancer cell growth. Eur. J. Pharm. Biopharm. 79(2), 268–275 (2011).
  Medline CASGoogle Scholar
• 78. Lai W-F, Tang R, Wong W-T. Ionically crosslinked complex gels loaded with oleic acid-containing vesicles for transdermal drug delivery. Pharmaceutics 12(8), 725 (2020).
  Medline CASGoogle Scholar
• 79. Liu K, Chen W, Yang T et al. Paclitaxel and quercetin nanoparticles co-loaded in microspheres to prolong retention time for pulmonary drug delivery. Int. J. Nanomed. 12, 8239–8255 (2017).
  Medline CASGoogle Scholar
• 80. Daglioglu C. Enhancing tumor cell response to multidrug resistance with pH-sensitive quercetin and doxorubicin conjugated multifunctional nanoparticles. Colloids Surf. B Biointerfaces 156, 175–185 (2017).
  Medline CASGoogle Scholar
• 81. Arbain NH, Salim N, Masoumi HRF, Wong TW, Basri M, Abdul Rahman MB. In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery. Drug Deliv. Transl. Res. 9(2), 497–507 (2019).
  Medline CASGoogle Scholar
• 82. Arbain NH, Salim N, Wui WT, Basri M, Rahman MBA. Optimization of quercetin loaded palm oil ester based nanoemulsion formulation for pulmonary delivery. J. Oleo Sci. 67(8), 933–940 (2018).
  Medline CASGoogle Scholar
• 83. Zhou X, Liu HY, Zhao H, Wang T. RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment. Onco. Targets Ther. 11, 5397–5405 (2018).
  Medline CASGoogle Scholar
• 84. Baksi R, Singh DP, Borse SP, Rana R, Sharma V, Nivsarkar M. In vitro and in vivo anticancer efficacy potential of quercetin loaded polymeric nanoparticles. Biomed. Pharmacother. 106, 1513–1526 (2018).
  Medline CASGoogle Scholar
• 85. Riaz MK, Zhang X, Wong KH et al. Pulmonary delivery of transferrin receptors targeting peptide surface-functionalized liposomes augments the chemotherapeutic effect of quercetin in lung cancer therapy. Int. J. Nanomed. 14, 2879–2902 (2019).
  Medline CASGoogle Scholar
• 86. Lai W-F, Gui D, Wong M et al. A self-indicating cellulose-based gel with tunable performance for bioactive agent delivery. J. Drug Deliv. Sci. Technol. 63, 102428 (2021).
  CASGoogle Scholar
• 87. Rofeal MG, Elzoghby AO, Helmy MW, Khalil R, Khairy H, Omar S. Dual therapeutic targeting of lung infection and carcinoma using lactoferrin-based green nanomedicine. ACS Biomater. Sci. Eng. 6(10), 5685–5699 (2020).
  Medline CASGoogle Scholar
• 88. Sun X, Li Y, Xu L et al. Heparin coated meta-organic framework co-delivering doxorubicin and quercetin for effective chemotherapy of lung carcinoma. J. Int. Med. Res. 48(2), 300060519897185 (2020).
  MedlineGoogle Scholar
• 89. Shen Y, Tantai J. Co-delivery anticancer drug nanoparticles for synergistic therapy against lung cancer cells. Drug Des. Devel. Ther. 14, 4503–4510 (2020).
  Medline CASGoogle Scholar
• 90. Wang Y, Yu H, Wang S et al. Targeted delivery of quercetin by nanoparticles based on chitosan sensitizing paclitaxel-resistant lung cancer cells to paclitaxel. Mater. Sci. Eng. C Mater. Biol. Appl. 119, 111442 (2021).
  Medline CASGoogle Scholar
• 91. Khorsandi L, Mansouri E, Rashno M, Karami MA, Ashtari A. Myricetin loaded solid lipid nanoparticles upregulate MLKL and RIPK3 in human lung adenocarcinoma. Int. J. Pept. Res. Ther. 26(2), 899–910 (2019).
  Google Scholar
• 92. Nafee N, Gaber DM, Elzoghby AO, Helmy MW, Abdallah OY. Promoted antitumor activity of myricetin against lung carcinoma via nanoencapsulated phospholipid complex in respirable microparticles. Pharm. Res. 37(4), 82 (2020).
  Medline CASGoogle Scholar
• 93. Song Y, Zhou B, Du X et al. Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small-cell lung cancer (NSCLC). Biomed. Pharmacother. 125, 109561 (2020).
  Medline CASGoogle Scholar
• 94. Bharathi D, Ranjithkumar R, Chandarshekar B, Bhuvaneshwari V. Bio-inspired synthesis of chitosan/copper oxide nanocomposite using rutin and their activity in human lung cancer cells. Int. J. Biol. Macromol. 141, 476–483 (2019).
  Medline CASGoogle Scholar
• 95. Paudel KR, Wadhwa R, Tew XN et al. Rutin loaded liquid crystalline nanoparticles inhibit non-small-cell lung cancer proliferation and migration in vitro. Life Sci. 276, 119436 (2021). • Focus on flavone-loaded nanotherapeutics in lung cancer therapy.
  Medline CASGoogle Scholar
• 96. Jiang J, Mao Q, Li H, Lou J. Apigenin stabilized gold nanoparticles increased radiation therapy efficiency in lung cancer cells. Int. J. Clin. Exp. Med. 10, 13298–13305 (2017).
  Google Scholar
• 97. Jin X, Yang Q, Zhang Y. Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer. Int. J. Nanomed. 12, 5109–5118 (2017).
  Medline CASGoogle Scholar
• 98. Mahmoudi S, Ghorbani M, Sabzichi M, Ramezani F, Hamishehkar H, Samadi N. Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells. J. Drug Deliv. Sci. Technol. 49, 268–276 (2019).
  CASGoogle Scholar
• 99. Sen R, Ganguly S, Ganguly S et al. Apigenin-loaded PLGA-DMSA nanoparticles: a novel strategy to treat melanoma lung metastasis. Mol. Pharm. 18(5), 1920–1938 (2021).
  Medline CASGoogle Scholar
• 100. Majumdar D, Jung KH, Zhang H et al. Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev. Res. (Phila.) 7(1), 65–73 (2014).
  Medline CASGoogle Scholar
• 101. Li J, Cheng X, Chen Y et al. Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: an in vivo/in vitro evaluation. Int. J. Pharm. 512(1), 262–272 (2016). • Focus on flavanone-loaded nanotherapeutics in lung cancer therapy.
  Medline CASGoogle Scholar
• 102. Wolfram J, Scott B, Boom K et al. Hesperetin liposomes for cancer therapy. Curr. Drug Deliv. 13(5), 711–719 (2016).
  Medline CASGoogle Scholar
• 103. Kumar SP, Birundha K, Kaveri K, Devi KT. Antioxidant studies of chitosan nanoparticles containing naringenin and their cytotoxicity effects in lung cancer cells. Int. J. Biol. Macromol. 78, 87–95 (2015).
  Medline CASGoogle Scholar
• 104. Parashar P, Tripathi CB, Arya M et al. Biotinylated naringenin intensified anticancer effect of gefitinib in urethane-induced lung cancer in rats: favourable modulation of apoptotic regulators and serum metabolomics. Artif. Cells Nanomed. Biotechnol. 46(Suppl. 3), S598–S610 (2018).
  Medline CASGoogle Scholar
• 105. Parashar P, Rathor M, Dwivedi M, Saraf SA. Hyaluronic acid decorated naringenin nanoparticles: appraisal of chemopreventive and curative potential for lung cancer. Pharmaceutics 10(1), 33 (2018).
  MedlineGoogle Scholar
• 106. Md S, Alhakamy NA, Aldawsari HM et al. Formulation design, statistical optimization, and in vitro evaluation of a naringenin nanoemulsion to enhance apoptotic activity in A549 lung cancer cells. Pharmaceuticals (Basel) 13(7), 152 (2020).
  Medline CASGoogle Scholar
• 107. Morais RP, Novais GB, Sangenito LS et al. Naringenin-functionalized multi-walled carbon nanotubes: a potential approach for site-specific remote-controlled anticancer delivery for the treatment of lung cancer cells. Int. J. Mol. Sci. 21(12), 4557 (2020).
  Medline CASGoogle Scholar
• 108. Wang Z, Liu L, Yin W, Liu Z, Shi L, Tang M. A novel drug delivery system: the encapsulation of naringenin in metal–organic frameworks into liposomes. AAPS PharmSciTech 22(2), 61 (2021). • Focus on isoflavone-loaded nanotherapeutics in lung cancer therapy.
  Medline CASGoogle Scholar
• 109. Dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLOS ONE 6(9), e24438 (2011).
  MedlineGoogle Scholar
• 110. Kamel NM, Helmy MW, Samaha MW, Ragab D, Elzoghby AO. Multicompartmental lipid–protein nanohybrids for combined tretinoin/herbal lung cancer therapy. Nanomedicine (Lond.) 14(18), 2461–2479 (2019).
  CASGoogle Scholar
• 111. Kamel NM, Helmy MW, Abdelfattah EZ et al. Inhalable dual-targeted hybrid lipid nanocore-protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells. ACS Biomater. Sci. Eng. 6(1), 71–87 (2020).
  Medline CASGoogle Scholar
• 112. Sacko K, Thangavel K, Shoyele SA. Codelivery of genistein and miRNA-29b to A549 cells using aptamer-hybrid nanoparticle bioconjugates. Nanomaterials (Basel) 9(7), 1052 (2019).
  Medline CASGoogle Scholar
• 113. Jin K, Yan Y, Chen M et al. Multimodal deep learning with feature level fusion for identification of choroidal neovascularization activity in age-related macular degeneration. Acta Ophthalmol. 100(2), e512–e520 (2022).
  MedlineGoogle Scholar
• 114. Elbaz S. Therapeutic effect of luteolin natural extract versus its nanoparticles on tongue squamous cell carcinoma cell line. (NCT03288298) (2017).
  Google Scholar